{"prompt": "['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 36 of 51', 'Study ID RCB: 2020-A00652-37', 'in the multivariate model. The results of univariate and multivariate analyses will be', 'interpreted in terms of odds-ratios with their 95% confidence intervals', 'In case of correlated variables, only the more significant in univariate will be include in the', 'multivariate model.', 'Variables with a rate of missing data 20%, or those with empty categories or with very small', 'number will not be considered eligible for this research of predictive factors.', 'As part of one of the secondary objectives, the analyses performed for the efficacy endpoint', 'are summarized in the table below :', 'Objective', 'Statistical analysis', 'Exposure measure', 'Outcome measure', 'Covariables', '2.a', 'Proportions', 'N/A', 'Achievement of the', 'N/A', 'main goal (yes/no) at', '12/16 weeks', '2.b', 'Proportions -', 'N/A', 'Achievement of the', 'N/A', 'sensitivity analysis', 'main goal (yes/no) at', '12/16 weeks', '2.c', 'Binary logistic', 'N/A', 'Achievement of the', 'Relevant', 'regression models,', 'main goal (yes/no) at', 'confounders (eg :', '12/16 weeks', 'demographic data,', 'medical history,', 'previous treatment...)', '2.d', 'Proportions', 'N/A', 'Achievement of the', 'N/A', 'main goal (yes/no) at', '12/16 weeks for each', 'component', '9.8.5', 'Other secondary analyses', '-', 'Description and evolution of PASI', 'The PASI score will be described at baseline, W12/16 and W52.', 'The change in the PASI score between baseline and W12/16 then between baseline and W52', 'will be described by summary descriptive statistics, including 95% confidence interval of the', 'mean.', '-', 'Evolution of DLQI', 'The change in the DLQI score between baseline and W12/16 then between baseline and W52', 'will be described by summary descriptive statistics, including 95% confidence interval of the', 'mean.', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 37 of 51', 'Study ID RCB: 2020-A00652-37', '-', 'Level of agreement between the dimensions reported by the patient and by the treating', 'physician.', 'The proportion of concordant / discordant choices between the dimensions selected at', 'baseline by patient and the physician will be described.', 'The level of agreement could be evaluated with a Kappa coefficient. Results will be provided', 'in both a quantitative and a qualitative way using the following classes : <0 =\" no agreement 11,', '[0 ; 0.20]=\" slight agreement 11, 00.20; 0.40]=\" fair agreement \", ]0.40 ; 0.60]=\" moderate', 'agreement \", 00.60 ; 0.80]= substantial agreement \" et ]0.80 ; 1]=\" almost perfect', 'agreement \".', '-', 'Maintenance of target objective at W52', 'The Maintenance of the main treatment goal will be defined as a \"satisfied or very satisfied\"', 'response at W52 for patients who have achieved their initial treatment goal at W12/16.', 'The proportion of patients with maintenance of their main treatment goal at W52 will be', 'described.', '- Change of therapeutic objective at the 1st follow-p visit (W12/16).', 'The proportion of patients who changed their main treatment goal at W12/16 will be', 'described.', '-', 'Level of accordance between PASI 90 and the satisfaction level in regard to the', 'therapeutic objective set by the PSO-TARGET QoL Component grid.', '-', 'The change in the PASI scorebetween baseline and the 1st follow-up visit (W 12/16) will be', 'described according to the level of achievement of the main treatment goal (achieved or', 'not). The percentages of patients with a PASI 90 that responded \"satisfied or very', 'satisfied\" on the Likert scale at 12 weeks will be calculated and will be compared to the', 'percentages of patients with a PASI>90 that responded \"unsatisfied or very unsatisfied\",', 'using a khi\u00b2 analysis. In case the populations are too small, a Fisher exact test will be used.', 'The analyses performed for the secondary endpoints are summarized in the table below :', 'Objective', 'Statistical analysis', 'Exposure measure', 'Outcome measure', 'Covariables', '1', 'Contingency table;', 'N/A', 'Concordance level', 'N/A', 'Sensitivity /', 'between PSO-', 'Specificity', 'TARGET Component', 'grid and DLQI at', '12/16 weeks', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']\n\n###\n\n", "completion": "END"}